<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055143</url>
  </required_header>
  <id_info>
    <org_study_id>PKD/08/038</org_study_id>
    <nct_id>NCT03055143</nct_id>
  </id_info>
  <brief_title>Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer</brief_title>
  <official_title>A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study Of Doxorubicin Hydrochloride Liposome Injection, 2 mg/ml (50 mg/m2 Dose) of Sun Pharma Advanced Research Company Limited, India, And CaelyxÂ® (Doxorubicin Hydrochloride) Liposome Injection, 2 mg/ml (50 mg/m2 Dose) of Schering-Plough, Belgium, in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer, Under Fed (Normal Breakfast) Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomized, multi centre, open label, two treatment, two period, two sequence,
      single dose, crossover study, with at least 28 days washout between doses, conducted under
      fed (normal breakfast) conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2008</start_date>
  <completion_date type="Actual">November 28, 2009</completion_date>
  <primary_completion_date type="Actual">November 28, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum measured plasma concentration</measure>
    <time_frame>336 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The area under the plasma concentration versus time curve from time 0 to infinity</measure>
    <time_frame>336 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Breast Cancer and Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>SPARC-08-038</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ref-08-038</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC-08-038</intervention_name>
    <description>2 mg/ml intravenous infusion</description>
    <arm_group_label>SPARC-08-038</arm_group_label>
    <arm_group_label>Ref-08-038</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ref-08-038</intervention_name>
    <description>2 mg/ml intravenous infusion</description>
    <arm_group_label>SPARC-08-038</arm_group_label>
    <arm_group_label>Ref-08-038</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Availability of volunteer for the entire study period and willingness to adhere to
             protocol requirements as evidenced by written informed consent.

          2. Patients with metastatic breast cancer/advanced ovarian cancer having age within the
             range of between 18-55 years.

          3. Subjects who had no evidence of underlying disease

          4. Subjects who had signed written consent form

        Exclusion Criteria:

          1. Females who were pregnant, breastfeeding, or are likely to become pregnant

          2. Subjects who had any medical condition (except metastatic breast cancer/advanced
             ovarian cancer) that could jeopardize their health or prejudice the results

          3. Subjects deemed uncooperative or noncompliant

          4. Smoking or consumption of any nicotine products
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

